Cordis Announces Innovative Results from Groundbreaking Trials

Groundbreaking Results on Coronary Artery Disease Treatment

Cordis, a leader in interventional cardiovascular solutions, has unveiled the significant outcomes from the SELUTION DeNovo and SELUTION4ISR trials. These trials were presented at the prestigious Transcatheter Cardiovascular Therapeutics (TCT) 2025 event, showcasing a new era in how coronary artery disease (CAD) is approached.

SELUTION DeNovo Trial: A Milestone in Drug Eluting Balloon Technology

The SELUTION DeNovo trial marks a pivotal point in cardiovascular research, standing as the largest randomized trial focused on Drug Eluting Balloons (DEB). The trial effectively demonstrated that the SELUTION SLR™ DEB treatment strategy is non-inferior when compared to traditional Drug Eluting Stent (DES) strategies for treating de novo coronary lesions.

Key Outcomes of the Trial

Involving 3,323 patients from 62 sites globally, this trial set a record in the field of coronary DEB studies. The results revealed that SELUTION SLR™ DEB achieved target vessel failure (TVF) rates of 5.3% at 12 months, closely aligning with the DES arm at 4.4%. This compelling evidence provides robust support for considering SELUTION SLR™ DEB as a viable alternative to DES.

Expert Insights on the Findings

Professor Christian Spaulding, a co-principal investigator, emphasized the transformative nature of these findings. He noted that these results could alter the landscape of Percutaneous Coronary Intervention (PCI), allowing practitioners to minimize the reliance on stents while still ensuring effective coronary treatment options. This shift is significant for patient care, offering a safer and more effective approach with SELUTION SLR™ DEB.

SELUTION4ISR Trial: A Study on In-Stent Restenosis

The SELUTION4ISR trial also yielded promising results, focusing on patients with In-Stent Restenosis (ISR). This multicenter randomized controlled study noted that SELUTION SLR™ DEB displayed non-inferiority when compared to current ISR treatment standards. Target lesion failure (TLF) at 12-months was noted at 15.2% for SELUTION SLR™ DEB against 13.5% for standard care, showcasing the effectiveness of this treatment option.

Potential Regulatory Advancements

This positive outcome sets the stage for Cordis to pursue regulatory approval for the coronary ISR indication with the FDA. Dr. Roxana Mehran, another co-principal investigator, stated that SELUTION SLR™ DEB offers a durable solution that addresses the challenges associated with ISR without the complications that additional metal stents introduce.

Cordis' Commitment to Innovation and Patient Care

The results from both trials indicate Cordis' unwavering commitment to advancing cardiovascular treatment through innovative solutions. As a leader in the cardiac intervention arena, Cordis aims to enhance the application of drug-eluting balloons within PCI strategies.

Future Directions

With over 17,000 patients enrolled in their clinical portfolio for the SELUTION SLR™ DEB, Cordis emphasizes the importance of collaborative endeavors to push forward with meaningful innovations. The commitment to research and development will continue to evolve the treatment landscape for coronary artery disease, ultimately benefiting countless patients.

Experts Recognize Groundbreaking Contributions

Dr. Martin Leon, Chair of the Cordis Clinical Advisory Board, praised the efforts demonstrated through the SELUTION studies, citing that the findings deliver safe and effective alternatives for treating complex lesions, further enhancing patient outcomes.

About SELUTION SLR™ DEB and Cordis

SELUTION SLR™ DEB, which is commercially available in over 65 countries, is distinguished by its Sustained Limus Release (SLR) technology. This technology allows for controlled and sustained drug release for 90 days, effectively targeting the complications associated with restenosis.

Cordis has been a forerunner in cardiovascular innovation for more than six decades, introducing pioneering products that have significantly shaped the field. The organization's focus on improved clinical outcomes and customer service reflects their ongoing mission to enhance cardiovascular care for patients globally.

Frequently Asked Questions

What are the main results of the SELUTION DeNovo trial?

The SELUTION DeNovo trial showed that the SELUTION SLR™ DEB was non-inferior to drug-eluting stents in treating coronary lesions.

How many patients were involved in the SELUTION4ISR trial?

The SELUTION4ISR trial enrolled a diverse cohort of patients across multiple global sites, demonstrating crucial efficacy compared to the standard of care.

What technology does SELUTION SLR™ DEB use?

SELUTION SLR™ DEB utilizes Sustained Limus Release technology for controlled drug elution to manage restenosis effectively.

What is the potential regulatory impact of these studies?

The positive results from the trials may support Cordis in seeking FDA approval for the SELUTION SLR™ DEB's application in ISR treatment.

How has Cordis contributed to cardiovascular treatment advancements?

Cordis has consistently driven innovation in cardiovascular technology, reshaping how coronary artery disease is treated over the last 60 years.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.